This early period is primarily about protocol establishment, tolerance assessment, and getting both compounds into a consistent daily routine
The ability to return to activities abandoned due to chronic pain, improved quality of life, and sustained relief rather than temporary symptom reduction characterize successful long-term protocols
Six passed BPC-157, KPV, and TB-500 each by an 8-6 margin, MOTS-C by 7-5, Semax by 8-5, and Epitalon by 7-5
Finally, BPC 157 is listed as a prohibited substance by the World Anti-Doping Agency (WADA), all NCAA, and all professional anti-doping sporting agencies
The trade-off is higher cost and the requirement for clinical administration